Navigation Links
eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008
Date:10/9/2008

PHILADELPHIA, Oct. 9 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device, and related industries, announced today that it will release its 2008 third quarter results for the period ended September 30, 2008 on Thursday, October 30, 2008 after the market closes. After the release, the Company will host a conference call at 5:00 PM EDT that day.

For the conference call, interested participants should dial 1-866-277-1181 when calling within the United States or 1-617-597-5358 when calling internationally. Please use pass code 54904519. There will be a playback available as well. To listen to the playback, please call 1-888-286-8010 when calling within the United States or 1-617-801-6888 when calling internationally. Please use pass code 17782796 for the replay.

This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.eRT.com. The webcast may also be accessed at Thomson's Institutional Investor website at http://phx.corporate-ir.net/playerlink.zhtml?c=119164&s=wm&e=1991822. The webcast can be accessed for up to one year on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2008 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008
2. eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008
3. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
4. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
7. Pathwork Diagnostics Announces Key Additions to Management Team
8. The Michigan Life Sciences Pipeline Announces The Funding Place(TM) and Other Resources to Connect Investors and Startups
9. Radi Medical Systems Announces Schedule for TCT 2008
10. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
11. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Acupath Laboratories, Inc., a leading provider ... an Executive Committee that will guide the company,s vision ... John Cucci , a 15-year veteran of the anatomic ... Development to Chief Sales Officer .  Prior to ... senior sales leadership roles at several leading lab industry ...
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... 18, 2017   Parent Project Muscular Dystrophy (PPMD) ... Duchenne muscular dystrophy (Duchenne) , today announced a ... Institute of Technology (NJIT) and Talem Technologies (Talem) as ... technology to assist people living with Duchenne. PPMD ... – an embedded computer, software, a force sensor and ...
Breaking Biology Technology:
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
Breaking Biology News(10 mins):